Skip to main content
Skip to content
This is a FedEx invoice for account number 1144-2081-6, held by Jeffrey E. Epstein, detailing five s...Academic analysis of state victim‑rights statutes and the federal CVRA
Case File
d-14570House OversightOther

Biotech IPO market analysis mentions JOBS Act and testing‑the‑waters meetings

The passage only discusses market trends, the JOBS Act, and generic investor behavior. It contains no specific individuals, transactions, dates, or allegations linking powerful actors to misconduct, o Mentions the JOBS Act as a factor in expanding biotech IPO activity References “testing the waters” meetings as a tool for fund managers Provides aggregate data on IPO counts and capital raised (2004

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024041
Pages
1
Persons
0
Integrity
No Hash Available

Summary

The passage only discusses market trends, the JOBS Act, and generic investor behavior. It contains no specific individuals, transactions, dates, or allegations linking powerful actors to misconduct, o Mentions the JOBS Act as a factor in expanding biotech IPO activity References “testing the waters” meetings as a tool for fund managers Provides aggregate data on IPO counts and capital raised (2004

Tags

biotechjobs-actipoinvestmentmarket-analysishouse-oversight
View on oversight.house.gov
Browse House Oversight Committee ReleasesHouse Oversight #024041

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
investors to grasp the complexities and opportunities of the small biotech companies before the formal filing of their IPO registration statements, and the start of the traditional IPO road show. The Fund Managers believe the JOBS Act and the use of “testing the waters meetings” has been one of the factors that helped open the current biotech IPO window, expanded the base of investors (public market specialist and generalist investors) participating in the recent offerings, and helped drive the after-market performance of many of these offerings. 25 20 # of IPOs 15 Capital Raised ($ in millions) 10 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014Q1 (M@@@miPre-Phase3 MEMMPhase3 MEMMMarketed =e=—#of IPOs The combination of all of these positive factors has significantly strengthened the position of smaller development and early commercial stage healthcare technology companies, and creates a unique period of opportunity for investors in the sector.

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

DonateMore ways to support →
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.